Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.

By David J. Scott, C. Stohler, C. M. Egnatuk, Heng Wang, Robert A. Koeppe, Jon-Kar Zubieta. Archives of General Psychiatry, 2008

622 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Cognitive Neuroscience, Physiology

View Paper: https://www.semanticscholar.org/paper/45ae4f5cbd57144e800b37ea2fa1022532c6fcfb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

In Physiology

Citations in the corpus

The placebo effect: From concepts to genes. (2015, positive): “For example, the activation of dopamine (and opioid) neurotransmission was explored during a placebo manipulation with changes in the binding potential of carbon 11 [11C]-labeled raclopride (and [11C] carfentanil) in a PET study (Scott et al., 2008).”
Neuroimaging of the Periaqueductal Gray: State of the Field (2011, background): “A negative relationship between PAG opioid activity during placebo and that of the nucleus accumbens and the amygdala, and a trend towards a negative correlation to the subgenual anterior cingulate, has also been reported (Scott et al., 2008).”
Activation of the opioidergic descending pain control system underlies placebo analgesia. (2009, background): “…Grevert et al., 1983; Levine and Gordon, 1984; Levine et al., 1978) and positron emission tomography (PET) studies using m-opioid selective tracers (Scott et al., 2008; Wager et al., 2007; Zubieta et al., 2005) have identified an important role of the endogenous opioid system in both clinical…”
Placebo Effects: Biological, Clinical and Ethical Advances (2010, positive): “A deactivation of dopamine has also been found in the nucleus accumbens during nocebo hyperalgesia (66), which indicates the involvement of different neurotransmitters.”
Traditional Chinese Acupuncture and Placebo (Sham) Acupuncture Are Differentiated by Their Effects on μ-Opioid Receptors (MORs) (2009, background): “Reduction in central MOR BP during SA is consistent with increased endogenous opioid release during placebo administration (Zubieta et al., 2005; Scott et al., 2008).”